Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Alzheimer's Disease
Interventions
DRUG

rivastigmine patch

rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks

Trial Locations (16)

Unknown

Holy Family Hospital, The Catholic Univerisy of Korea, School of Medicine, Bucheon-si

Busan National University Hospital, Busan

Busan Paik Hospital, Inje University College of Medicine, Busan

Changwon Fatima Hospital, Changwon

Daegu Fatima Hospital, Daegu

Keimyung University School of Medicine, Daegu

Kyungpook National University School of Medicine, Daegu

Myongji Hospital, Kwandong University College of Medicine, Goyang

Dongguk University International Hospital, Ilsan

National Health Insurance Corporation Ilsan Hospital, Ilsan

Inha University College of Medicine, Incheon

Gyeongsang National University College of Medicine, Jinju

Chonnam National University, Medical School, Kwangju

Seoul National Unviersity College of Medicine, Clinical neuroscience center, Seoul National Unviersity Bundang Hospital, Seongnam

The Catholic Univerisy of Korea, School of Medicine, Seoul

Pusan National University Yangsan Hospital, Yangsan

All Listed Sponsors
collaborator

Novartis Korea Ltd.

INDUSTRY

lead

Dong-A University

OTHER

NCT01380288 - Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine | Biotech Hunter | Biotech Hunter